New drug lasts for a week and is more effective than conventional drugs – healing practice

Once-a-week injection could revolutionize diabetes treatment

diabetics are often on the splash of insulin responsible for keeping the disease under control. However, currently available means can only reduce insulin levels max 24 hours Check. A new diabetes drug that only once a week according to a recent study more efficient and at the same time more tolerable be.

Recently published research results on the German Diabetes Society Autumn Conference were presented in Wiesbaden, show that the new diabetes drug insulin icodecwhich should only be administered once a week, is more effective, more popular and better tolerated than insulin degludecwhich must be taken daily.

A new diabetes drug that is more effective, better tolerated and more popular

Phase III study results for the new diabetes drug, insulin icodec, are promising. The task force judged the drug to be more effective than insulin degludec, a common diabetes drug. At the same time, it was more popular with those tested and was perceived as more tolerable.

Long-term blood sugar can be lowered more effectively

In the study, 236 patients received the new drug for 26 weeks. A comparison group of 263 participants took the already available insulin degludec instead.

After 26 weeks of use, researchers found that the HbA1c value was lower in the insulin icodec group than in the insulin degludec group (0.93 versus 0.71%). The HbA1c value provides information about the level blood sugar over the past 8 to 12 weeks.

New remedy associated with slight weight gain

The only drawback of the new drug, which could have consequences that should not be underestimated: in the icodec group, participants increased by an average of 26 weeks 1.4kg increased, while subjects in the degludec group lost 0.3 kg.

New diabetes drug is ‘significantly superior’

“In patients with type 2 diabetes who were previously treated with basal insulin, insulin icodec is significantly superior to insulin degludec in terms of HbA1c reduction and treatment satisfaction”summarizes the working group.

Affected people could have their injections a year with the new agent Reduction from 365 to 52 syringes. Since this is already a phase 3 study that was conducted on humans and there are no safety concerns with its use, approval could now be granted quickly. (vb)